Yoga treatment for overactive bladder in kids
Yoga for Treatment of Overactive Bladder in Pediatric Patients
This study is testing if yoga can help kids aged 8-18 with overactive bladder feel better after six weeks of weekly sessions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 8 Years to 18 Years |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT05895045 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of yoga as a treatment for pediatric patients aged 8-18 diagnosed with idiopathic overactive bladder. Participants will engage in weekly yoga sessions for six weeks, with their symptoms assessed through validated questionnaires and urinary biomarkers at the start, middle, and end of the study. The study employs a cross-over design, allowing participants to receive standard care when not in the active treatment phase. The goal is to determine if yoga can alleviate symptoms associated with overactive bladder in this population.
Who should consider this trial
Good fit: Ideal candidates are children aged 8-18 with a diagnosis of non-neurogenic overactive bladder or detrusor overactivity.
Not a fit: Patients with known neurogenic bladder conditions or untreated anatomical abnormalities of the lower urinary tract may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive treatment option for children suffering from overactive bladder symptoms.
How similar studies have performed: While yoga has shown benefits in various pediatric conditions, this specific application for overactive bladder in children is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 8-18 years of age * History of non-neurogenic overactive bladder or detrusor overactivity and/or urinary incontinence (ICD 10 codes respectively - N32.81, N39.498) * Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent/legal guardian * Minor participant is willing and able to provide assent (as applicable) * Vancouver Dysfunctional Elimination Syndrome\[15\] score of ≥11 and a positive modified bother score within 30 days of consent Exclusion Criteria: * Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele) * Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord) * Nerve damage that may impact pelvic floor function * History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin) * Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable) * Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential * Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety
Where this trial is running
Durham, North Carolina
- Duke University Hospital — Durham, North Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Rafael Tua-Caraccia, MD
- Email: rdt25@duke.edu
- Phone: 7865546150
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.